The use of psychopharmacological and other treatments by persons with psychosis

Morgan, Vera; Castle, David; Jablensky, Assen

doi:10.1037/e677362010-001

“…For those with schizophrenia treated largely in public settings, depots are prescribed in 25% 32 to 42% 33 of patients in Australia and in 24% in New Zealand 34 . In both countries, this contrasts with the high uptake of oral SGAs.…”

Section: Those Treated With First Generation Depot Antipsychoticsmentioning

confidence: 99%

Selecting Patients for Long-acting Novel Antipsychotic Therapy

Lambert

¹

2006

Australas Psychiatry

View full text Add to dashboard Cite

Optimizing outcome for patients with enduring psychotic disorders involves enabling a stable psychopharmacological platform upon which to build a psychosocial therapies programme. Too often, problems with adherence undermine the recovery process. Long-acting novel antipsychotics ensure adherence, with all the advantages inherent in second-generation antipsychotics. Identifying patients a priori who might best respond to the long-acting novel antipsychotics may lead to improving the efficiency of the recovery process.

show abstract

“…For those with schizophrenia treated largely in public settings, depots are prescribed in 25% 32 to 42% 33 of patients in Australia and in 24% in New Zealand 34 . In both countries, this contrasts with the high uptake of oral SGAs.…”

Section: Those Treated With First Generation Depot Antipsychoticsmentioning

confidence: 99%

Selecting patients for long-acting novel antipsychotic therapy

Lambert

¹

2006

Australas Psychiat

1

0

View full text Add to dashboard Cite

Optimizing outcome for patients with enduring psychotic disorders involves enabling a stable psychopharmacological platform upon which to build a psychosocial therapies programme. Too often, problems with adherence undermine the recovery process. Long-acting novel antipsychotics ensure adherence, with all the advantages inherent in second-generation antipsychotics. Identifying patients a priori who might best respond to the long-acting novel antipsychotics may lead to improving the efficiency of the recovery process.

show abstract

“…The guidelines also endorse atypical antipsychotics as the first‐line treatment for schizophrenia because they are better tolerated in the short term by the vast majority of patients 11 . Some have claimed that these outcomes could be achieved if the “typical” (first‐generation) agents were used in lower doses, 12 but there is increasing evidence that this is not the case, and in practical terms such low‐dose use of typicals is unlikely to be achievable. Used over longer periods, the atypical agents are showing a significant advantage in relapse prevention 13 and lower rates of tardive dyskinesia than the typical agents.…”

mentioning

confidence: 99%